Affiliation:
1. Department of Ophthalmology, University Münster, 48149 Münster, Germany
Abstract
We compare the short- and mid-term postoperative outcomes of the iStent inject® with its successor, the iStent inject® W. A retrospective monocentric study was performed to compare the iStent inject® used for cataract surgery with the iStent inject® W, also used for cataract surgery. The primary study endpoint was intraocular pressure (IOP) reduction six months after surgery. Six-month follow-up results were available for 35 eyes from 27 patients in the iStent inject® group and for 32 eyes from 25 patients in the iStent inject® W group. IOP reduction at six months post surgery was significantly greater in the iStent inject® W group (−2.2 mmHg [iStent inject® W] vs. −0.06 mmHg [iStent inject®], p = 0.037). There was a statistically greater decrease in glaucoma medication administration at six months in the iStent inject® group than in the iStent inject® W group (−1.28 agents vs. −0.62 agents, p = 0.007). These findings support the hypothesis that the superior positioning of the iStent inject® W (due to its larger base diameter) compared to the iStent Inject® leads to greater IOP reduction. Because of the short follow-up period, small study cohort, and differences in the number of glaucoma patients, the study results must be interpreted carefully.
Funder
Open Access Publication Fund of the University of Münster
Reference25 articles.
1. Special Commentary: Supporting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery: Summary of a Joint Meeting of the American Glaucoma Society and the Food and Drug Administration, Washington, DC, 26 February 2014;Caprioli;Ophthalmology,2015
2. Novel glaucoma procedures: A report by the American Academy of Ophthalmology;Francis;Ophthalmology,2011
3. Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-bypass for Open-angle Glaucoma: A Meta-analysis;Popovic;J. Curr. Glaucoma Pract.,2018
4. iStent® Trabecular Microbypass Stent: An Update;Resende;J. Ophthalmol.,2016
5. Five-Year, Prospective, Randomized, Multi-Surgeon Trial of Two Trabecular Bypass Stents versus Prostaglandin for Newly Diagnosed Open-Angle Glaucoma;Fechtner;Ophthalmol. Glaucoma,2019